LGVN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Longeveron Inc (LGVN) is not a strong buy for a beginner investor with a long-term focus at this time. The company's financial performance is weak, with declining revenue and EPS, and the technical indicators do not suggest a favorable entry point. Additionally, there are no strong positive catalysts or trading signals to justify immediate action.
The MACD histogram is negative and expanding, indicating bearish momentum. The RSI is neutral at 25.124, and moving averages are converging, suggesting no clear trend. The stock is trading near its support level (S1: 0.964), but the overall technical outlook is weak.
The longevity therapeutics market is projected to grow significantly by 2030, which aligns with the company's focus.
The company's financials show declining revenue (-39.47% YoY) and EPS (-7.41% YoY). Gross margin has also dropped significantly (-19.89% YoY). Analysts have lowered the price target from $3 to $2, reflecting reduced confidence in the stock's near-term potential.
In Q4 2025, revenue dropped to $365,000 (-39.47% YoY), while net income improved to -$5,444,000 (+33.40% YoY). However, EPS declined to -0.25 (-7.41% YoY), and gross margin fell to 70.41% (-19.89% YoY). Overall, the financial performance is weak.
Roth Capital maintains a Buy rating but has lowered the price target from $3 to $2. The firm expects top-line data from the ELPIS II study in Q3 2026, with a potential BLA filing in 2027 if results are positive.
